Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

August 30, 2027

Study Completion Date

November 30, 2027

Conditions
Ischemic Stroke, AcuteCerebrovascular DisordersBrain DisorderCentral Nervous System Diseases
Interventions
DRUG

Intra-arterial tenecteplase injection at the completion of thrombectomy

Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus

DRUG

Placebo

intra-arterial bolus of 0.9% Sodium Chloride solution

Trial Locations (13)

Unknown

RECRUITING

Gold Coast Univeristy Hospital, Gold Coast

RECRUITING

Royal Adelaide Hospital, Adelaide

NOT_YET_RECRUITING

Princess Alexandra Hospital, Brisbane

NOT_YET_RECRUITING

Royal Brisbane and Women's Hospital, Brisbane

NOT_YET_RECRUITING

Canberra Hospital, Canberra

RECRUITING

Alfred Hospital, Melbourne

RECRUITING

Austin Hospital, Melbourne

NOT_YET_RECRUITING

Monash Medical Centre, Melbourne

RECRUITING

Royal Melbourne Hospital, Melbourne

NOT_YET_RECRUITING

John Hunter Hospital, Newcastle

NOT_YET_RECRUITING

Fiona Stanley Hospital, Perth

NOT_YET_RECRUITING

Liverpool Hospital, Sydney

NOT_YET_RECRUITING

Royal North Shore Hospital, Sydney

All Listed Sponsors
lead

University of Melbourne

OTHER